Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

Table 2 Correlation of KRAS gene status and phosphatase and tensin protein expression with clinical response to cetuximab in previously treated colorectal cancer patients n (%)

	KRAS			PTEN
	Mutation	No mutation	P	Positive	Negative	P
CR	0 (0)	2 (5.1)	0.001	2 (5.4)	0 (0)	0.001
PR	1 (4.5)	16 (41.0)		16 (43.2)	1 (4.2)
SD	7 (31.8)	17 (43.6)		10 (27.0)	14 (58.3)
PD	14 (63.6)	4 (10.3)		9 (24.3)	9 (37.5)
Total	22 (100)	39 (100)		37 (100)	24 (100)